Start with the surprising number. A CRISPR patent search on PatentBear returns tens of thousands of records, and the year-over-year distribution doesn't look like a maturing field — it looks like one still climbing. The annual counts move from the low hundreds in 2015 into the multiple thousands per year by the mid-2020s. By the numbers, gene editing is still in its expansion phase.
Here's what's behind it. A decade after CRISPR's breakout, you'd expect the patent curve to flatten as the foundational claims settle. Instead, the filings keep coming, because the platform keeps branching: new Cas enzymes, base editors, prime editors, delivery methods, and disease-specific applications each open fresh patentable territory. The recent grant record shows this directly — the Broad Institute's US12644111B2 ("CRISPR enzymes and systems," 2026) is a new enzyme-and-system grant, not a re-assertion of old claims.
The activity also spreads across assignees, which is the tell that this is a field, not a monopoly. The recent CRISPR grant record includes the Broad Institute (US12644136B2, delivery to hematopoietic stem cells), Vertex on the application side (US12644137B2, hemoglobinopathies), and a long tail of universities and companies. Three filings pointing the same way isn't noise — it's a pattern of many players still staking claims.
A caution on reading these counts, because correlation isn't causation. A rising patent count doesn't prove rising innovation quality — it can reflect defensive filing, continuations, and thicket-building as much as genuine breakthroughs. The honest statement is narrow: filing velocity is high and not declining. What that velocity means for any one company's moat is a separate question the raw counts can't answer.
Still, the direction is informative for a generalist. When a technology's patent filings are still accelerating a decade after its debut, the commercial fight over who owns what is intensifying, not resolving. For investors and newcomers, that means licensing complexity — and litigation risk — is more likely to grow than shrink in the near term.
The bottom line, by the numbers: CRISPR is not a settled estate. The filing curve is still bending upward, the grants are spread across many assignees, and the platform keeps generating new patentable layers. Anyone treating gene-editing IP as "already decided" is reading a different chart than the one PatentBear's counts actually show.